We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients

A doctor holding a clipboard with a patient.
Credit: iStock.
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

OncoHost, has developed a novel computational model for predicting significant immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) based on proteomic profiling of pre-treatment blood samples. The study was conducted using OncoHost’s PROphet® platform and will be presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

 

Activation of the immune system by immune checkpoint inhibitors (ICIs) can result in complications known as immune-related adverse events (irAEs), which commonly affect the skin, liver, gastrointestinal tract, and endocrine organs, ranging in severity from mild (in the majority of cases) to life threatening. IrAEs can manifest at any point during a patient's treatment, with the highest incidence occurring within the first three months. While most resolve with the appropriate intervention, some may become chronic and require lifelong care.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
"While ICIs have shown success in treating non-small cell lung cancer, immune-related adverse events pose a complex challenge, complicating and affecting treatment efficacy and patients' quality of life,” said Yehonatan Elon, Ph.D., Chief Technology Officer at OncoHost. “The ability to anticipate the risk of irAEs in these patients prior to commencing treatment is a game-changer, as it enables the development of personalized management plans and strategies for risk reduction. We are excited about these results and look forward to improving the overall quality of cancer care for patients worldwide."

 

OncoHost’s predictive model was developed on a cohort of 426 ICI-treated NSCLC patients taking part in the company’s ongoing, multicenter PROPHETIC clinical trial (NCT04056247). Plasma samples and clinical data, including irAE occurrence, were collected, and deep proteomic profiling was conducted using SomaLogic’s (NASDAQ: SLGC) SomaScan platform, measuring the expression levels of approximately 7,000 proteins.

 

“It brings me great pride to witness the growth of our company, and the vast pipeline of indications that are coming to fruition through our PROphet® platform,” said Ofer Sharon, MD, CEO of OncoHost. “Our mission is to transform the approach to precision medicine for improved patient outcomes, and our scientific achievements are a testament to this dedication. The pressing concern regarding the lack of dependable pre-treatment biomarkers for predicting irAE development underscores a critical clinical need, and we are proud to spearhead the efforts to address this issue."